In Vivo CAR-T for Multiple Myeloma: Could It Improve Access and Skip Chemotherapy? | IMS 2026

Yi Lin, MD, PhD, of Mayo Clinic Rochester discusses in vivo CAR-T at IMS 2026 in Glasgow. Today's CAR-T requires collecting a patient's cells, waiting weeks for manufacturing and receiving chemotherapy beforehand. In vivo CAR-T delivers genetic material by IV so a patient's own T cells become CAR-T cells inside the body, which could ease treatment burden and improve access. This approach is still early: a newly opened phase 1 trial is focused first on safety and finding the right dose.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity

Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:

0:00 Introduction: Dr. Yi Lin, Mayo Clinic Rochester

0:23 How Standard (Ex Vivo) CAR-T Works Today

0:50 The Logistics Burden: Collection, Manufacturing, Chemo

1:17 How In Vivo CAR-T Is Different

2:11 Why This Could Reduce Treatment Burden for Patients

2:50 Why This Could Make CAR-T More Accessible

3:06 Current Trial Status: Phase 1 Safety and Dosing

3:28 The Vyriad Platform: A More Targeted Approach